Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1237Docetaxel 1227Oxaliplatin 1184Capecitabine 1176Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 639Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × tamibarotene × Clear all
NCT06983210 2025-08-14

GRAPE

Nagoya University

Phase 2 Recruiting
43 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05064618 2024-04-04

MIKE-1

Nagoya University

Phase 1/2 Unknown
55 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06085638 2024-03-07

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT00985530 2013-10-30

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Northwestern University

Phase 1 Terminated
4 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡